⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL31599906 | 0.98 | HRH3 (0.39) | — | |
| SCHEMBL16767298 | 0.86 | — | — | |
| SCHEMBL21892209 | 0.86 | — | — | |
| Hydrochloric Acid SCHEMBL31645128 | 0.84 | — | — | |
| Trifluoroacetic Acid SCHEMBL31470241 | 0.83 | KMT2A (0.43) | — | |
| SCHEMBL30759010 | 0.83 | HRH3 (0.41) | — | |
| SCHEMBL16767657 | 0.83 | HRH3 (0.37) | — | |
| SCHEMBL31511542 | 0.80 | HRH3 (0.44) | — | |
| SCHEMBL11573602 | 0.79 | SLC6A1 (0.31) | — | |
| SCHEMBL9112176 | 0.79 | HRH3 (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421887-B1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES AS (DK) | 2015-04-22 | — | — | EP | claimed |
| US-8828938-B2 | Method for the manufacture of degarelix | POLYPEPTIDE LABORATORIES A/S (DK) | 2014-09-09 | — | — | US | claimed |
| EP-2421887-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | Polypeptide Laboratories A/S (DK) | 2012-02-29 | — | — | EP | claimed |
| US-20120041172-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2012-02-16 | — | — | US | claimed |
| WO-2010121835-A1 | METHOD FOR THE MANUFACTURE OF DEGARELIX | POLYPEPTIDE LABORATORIES A/S (DK) | 2010-10-28 | — | — | WO | claimed |
| EP-0426562-B1 | 1-(4-Aminophenyl)-2-piperidinopropanone derivatives, process for their preparation and their therapeutic use | LAFON LABOR (FR) | 1994-03-16 | — | — | EP | claimed |
| EP-0426562-A1 | 1-(4-Aminophenyl)-2-piperidinopropanone derivatives, process for their preparation and their therapeutic use | LABORATOIRE L. LAFON (FR) | 1991-05-08 | — | — | EP | claimed |
| US-4051140-A | VANADIA CATALYST | THE LUMMUS COMPANY (US) | 1977-09-27 | — | — | US | claimed |
| JP-3209364-A | — | — | None | — | — | JP | disclosed |
| EP-4573095-A1 | PYRIDOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2025-06-25 | — | — | EP | disclosed |
| EP-4540255-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| WO-2025081019-A1 | KIF MODULATOR COMPOUNDS AND METHODS OF USE | IAMBIC THERAPEUTICS, INC. (US) | 2025-04-17 | — | — | WO | disclosed |
| WO-2024040131-A1 | PYRIDOPYRIMIDINE KRAS INHIBITORS | Treeline Biosciences, Inc. (US) | 2024-02-22 | — | — | WO | disclosed |
| WO-2023244615-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2023-12-21 | — | — | WO | disclosed |
| US-5290789-A | Antipsychotically effective compounds | STERLING WINTROP INC. (US) | 1994-03-01 | — | — | US | disclosed |
| US-5128349-A | Vasodilators; cardiovascular disorders | LABORATOIRE L. LAFON (FR) | 1992-07-07 | — | — | US | disclosed |
| JP-H03209364-A | 1-(4AMINOPHENYL)2-PIPERIDINOPROPANONE DERIVATIVE, PREPARATION PROCESS AND USE IN THERAPEUTICS | LAB L LAFON SA | 1991-09-12 | — | — | JP | disclosed |
| EP-0426562-A1 | 1-(4-Aminophenyl)-2-piperidinopropanone derivatives, process for their preparation and their therapeutic use | LABORATOIRE L. LAFON (FR) | 1991-05-08 | — | — | EP | disclosed |
| US-4057552-A | AMMONIATION, OXIDIZED VANADIUM OXIDE ON SUPPORT AS CATALYST | THE LUMMUS COMPANY (US) | 1977-11-08 | — | — | US | disclosed |
| US-4051140-A | VANADIA CATALYST | THE LUMMUS COMPANY (US) | 1977-09-27 | — | — | US | disclosed |